August 15
CUREator+ delivers $50m funding boost to commercially focused BioMedTech startups
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areVaxxas' proprietary Nanopatch™ technology is a needle-free vaccine delivery solution
View ProjectDeveloping a new class of therapeutics that enhance the function of beneficial proteins
View ProjectTargeting long non-coding RNAs for next generation cancer therapies
View ProjectHudson Institute of Medical Research is a leading Australian medical research institute recognised internationally for discovery science and translational research into reproductive health and pregnancy, infant and child health, inflammation and cancer.
ViewThe Centenary Institute is a world-leading independent medical research institute, closely affiliated to the University of Sydney and the Royal Prince Alfred Hospital. Our research focuses on three key areas: cancer, inflammation and cardiovascular disease. Our strength lays in uncovering disease mechanisms and applying this knowledge to improve diagnostics and treatments for patients.
ViewThe Telethon Kids Institute is the largest research institute in Western Australia, with a bold vision to improve the health and development of children through excellence in research. Focused on translation, the Institute’s researchers and clinicians work closely, together with our research collaborators across Australia and around the world, to maximise research impact. They have extensive experience in coordinating technology and pharmaceutical interventions – including industry-sponsored trials – across a variety of diseases affecting children
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreCUREator+ delivers $50m funding boost to commercially focused BioMedTech startups
Read moreVaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine
Read more